CellaVision AB
STO:CEVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (36.9), the stock would be worth kr236.6 (87% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.7 | kr126.4 |
0%
|
| 3-Year Average | 36.9 | kr236.6 |
+87%
|
| 5-Year Average | 41.8 | kr268.39 |
+112%
|
| Industry Average | 33.5 | kr214.84 |
+70%
|
| Country Average | 23.9 | kr153.39 |
+21%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
kr2.9B
|
/ |
Jan 2026
kr153.1m
|
= |
|
|
kr2.9B
|
/ |
Dec 2026
kr182.2m
|
= |
|
|
kr2.9B
|
/ |
Dec 2027
kr217.9m
|
= |
|
|
kr2.9B
|
/ |
Dec 2028
kr254.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| SE |
|
CellaVision AB
STO:CEVI
|
2.9B SEK | 19.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.4 |
| Median | 23.9 |
| 70th Percentile | 32.1 |
| Max | 8 163.4 |
Other Multiples
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
